Evidence overview
Omega-3
Omega-3 fatty acids are among the most-studied supplements in modern medicine, with a research base anchored in cardiovascular disease prevention, pregnancy outcomes, inflammatory conditions, and (more recently) cognitive and mood effects. The evidence has shifted over the past decade as several large megatrials produced more nuanced results than earlier observational studies suggested. Marine sources (fish, algae) are far better-studied than plant sources.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Long-chain polyunsaturated fatty acids that incorporate into cell membranes and serve as precursors to...
Study coverage
Study coverage by goal
PubMed counts for Omega-3 grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Omega-3.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Omega-3 fatty acids are among the most-studied supplements in modern medicine, with a literature spanning cardiovascular disease prevention, triglyceride reduction, pregnancy and infant outcomes (preterm birth, infant cognitive development), depression and other mood disorders, rheumatoid arthritis, dry eye disease, and (more recently) cognitive decline and inflammatory biomarkers. The marine forms (EPA and DHA from fish oil, krill oil, or algae) dominate the clinical literature; the plant-derived form (ALA from flaxseed and similar sources) converts to EPA/DHA inefficiently in humans, which is why most clinical evidence is from marine-sourced products.
The outcome dimensions covered most heavily are cardiovascular disease prevention (the longest-running research stream, including the major megatrials of the past decade), triglyceride reduction (one of the most-studied biochemical outcomes, with substantial meta-analytic synthesis), pregnancy outcomes including preterm birth prevention, inflammatory conditions including rheumatoid arthritis, depression and bipolar disorder (mixed but growing literature), and dry eye disease (where omega-3 has practice-guideline use in ophthalmology). The cardiovascular evidence has been the subject of recent reanalysis as the megatrials produced results more nuanced than the earlier observational studies and small trials had suggested.
Demographically, the literature is unusually broad: cardiovascular trials enroll adults across a wide age range with varying baseline risk; pregnancy trials enroll pregnant women across many countries; older adults dominate the cognitive-decline research. Form, dose, and EPA-to-DHA ratio vary substantially between trials, which has complicated meta-analysis. Background diet (especially habitual fish intake) is a major modifier that earlier trials rarely accounted for: trials enrolling populations with low baseline fish intake tend to show larger effects than trials enrolling populations with high baseline intake.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Omega-3 is generally well-tolerated at typical supplemental doses (1-4 g/day combined EPA+DHA). The most-common adverse effects are gastrointestinal: fishy aftertaste and burps, nausea, and loose stools, which improve with enteric-coated capsules or refrigeration. Bleeding risk has been a longstanding theoretical concern because omega-3 affects platelet function; rigorous systematic reviews have not found a clinically meaningful increase in bleeding risk at typical doses, including in patients on anticoagulants. The FDA permits up to 3 g/day combined EPA+DHA from supplements as generally safe, with higher doses recommended only under medical supervision. Drug interactions include theoretical additivity with anticoagulants (clinically less concerning than long-believed), antihypertensives, and certain medications metabolized through CYP3A4. People on anticoagulants or anticipating surgery should consult a clinician about timing.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Cochrane synthesis on omega-3 for primary and secondary cardiovascular disease prevention - the supplement's most-extensively studied and clinically-asked use. The field's gold-standard reference document on this question.
View on PubMedCochrane synthesis on omega-3 supplementation during pregnancy, particularly for preterm birth prevention. The field reference for the pregnancy use case, where omega-3 has substantial evidence anchored in WHO and obstetric-society positions.
View on PubMedUmbrella meta-analysis covering omega-3's effects on inflammatory biomarkers - the mechanistic basis often cited as a general benefit of the supplement. Provides supplement-level breadth across many inflammatory conditions in a single reference document.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the omega-3 literature at a general level. It does not address whether your habitual fish intake already provides adequate EPA and DHA, what dose or EPA-to-DHA ratio is right for your goal, whether you should choose fish oil, krill oil, or algae-derived omega-3 (each has trade-offs), or how omega-3 interacts with the medications and supplements you take. Background dietary intake is the single biggest modifier of who benefits from supplementation, which is a question the personalized report can address with your specific context.
Personalized to you
Get a personalized Omega-3 report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Omega-3 materially updates. No account required.